Beneficial effects of cholesterol absorption inhibitor,ezetimibe on impaired endothelial function in patients with metabolic syndrome.
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Ezetimibe (Primary)
- Indications Hypercholesterolaemia; Metabolic syndrome
- Focus Therapeutic Use
- Acronyms EZET
- 31 Jul 2017 Status changed from recruiting to discontinued.
- 19 Feb 2011 New trial record